

Glenmark launches antibacterial drug in US

The drug is a generic alternative of Fresenius Kabi 's Vancomycin Hydrochloride and has an estimated market of \$37.9 million for the 12-month period ending March 2026.



New Delhi: Mumbai-based Glenmark Pharmaceuticals, announced the launch of an antibacterial drug, Vancomycin Hydrochloride for Injection in the US.

The drug is a generic alternative of Fresenius Kabi 's Vancomycin Hydrochloride and has an estimated market of \$37.9 million for the 12-month period ending March 2026.

“The launch of Vancomycin Hydrochloride strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients.” said Marc Kikuchi, President and Business Head, North America, Glenmark.

News Source:

<https://pharma.economicstimes.indiatimes.com/news/drug-approvals-and-launches/glenmark-launches-antibacterial-drug-in-us/131188831>